Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556584 | 0.89 | NPC1 (0.59) | SMN1; SMN2NPC1RAB9AGAAHTT | |
| SCHEMBL3555354 | 0.77 | KDM4E (0.60) | MAPK8MAPK9MAPK10NPC1RAB9A | |
| SCHEMBL5297607 | 0.75 | HCAR2 (0.62) | SMN1; SMN2MAPK8MAPK9MAPK10NPC1 | |
| SCHEMBL3551017 | 0.75 | MAPK10 (0.53) | SMN1; SMN2MAPK8MAPK9MAPK10NPC1 | |
| SCHEMBL3558388 | 0.75 | NPC1 (0.48) | NPC1RAB9AMAPTADRB2MEN1 | |
| SCHEMBL3552611 | 0.74 | MMP3 (0.54) | SMN1; SMN2MAPK8MAPK9MAPK10NPC1 | |
| SCHEMBL3560676 | 0.74 | MAPK10 (0.46) | SMN1; SMN2MAPK8MAPK9MAPK10NPC1 | |
| SCHEMBL11817902 | 0.74 | MAPK8 (0.57) | SMN1; SMN2MAPK8MAPK9MAPK10RAB9A | |
| SCHEMBL3553708 | 0.72 | L3MBTL1 (0.56) | SMN1; SMN2NPC1RAB9AGAAHTT | |
| SCHEMBL3563299 | 0.72 | MAPK10 (0.55) | SMN1; SMN2MAPK8MAPK9MAPK10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732452-B2 | Thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1931651-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | US | disclosed |
| WO-2007039482-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | GPR84, GPR174, MRGPRX1 | SMN1; SMN2 3043/4885MAPK8 2450/4885MAPK9 3143/4885 |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | GPR84, GPR174, MRGPRX1 | SMN1; SMN2 3043/4885MAPK8 2450/4885MAPK9 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.